Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY: EBS )

8.300 +0.150 (+1.84%)
Official Closing Price Updated: 5:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS)
From Glancy Prongay & Murray LLP
Via Business Wire
Emergent BioSolutions Hopeful To Restart Vaccine Production, Plans To Submit Response To FDA Within Days
Emergent BioSolutions Inc (NYSE: EBS) said it hopes to respond to U.S. regulators within days on how to resolve the problems at its Baltimore plant, which have forced... 
Via Benzinga
Exposures Product Safety
EMERGENT INVESTORS: June 18, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
From Lieff Cabraser Heimann & Bernstein, LLP
Via Business Wire
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
Emergent BioSolutions Inc (EBS) Q1 2021 Earnings Call Transcript
EBS earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Emergent BioSolutions: Q1 Earnings Insights
Shares of Emergent BioSolutions (NYSE:EBS) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 15200.00% over the... 
Via Benzinga
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
EBS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Emergent BioSolutions Inc. Investors of Class Action and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
EMERGENT SHAREHOLDERS: June 18, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
From Lieff Cabraser Heimann & Bernstein, LLP
Via Business Wire
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... 
Via Benzinga
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS)
From Law Offices of Howard G. Smith
Via Business Wire
A Preview Of Emergent BioSolutions's Earnings
Emergent BioSolutions (NYSE:EBS) announces its next round of earnings this Thursday, April 29. Here is Benzinga's everything-that-matters guide for this Thursday's Q1 earnings... 
Via Benzinga
ROSEN, A TOP RANKED LAW FIRM, Encourages Emergent BioSolutions Inc. Investors with Losses to Secure Counsel Before Important Deadline – EBS
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Emergent BioSolutions Inc.’s Directors and Officers for Breach of Fiduciary Duties – EBS
From Scott+Scott Attorneys at Law LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Is There Any Hope Left for Emergent BioSolutions?
The go-to government contractor is in deep trouble. Should investors buy the dip? 
Via The Motley Fool
Exposures COVID-19
EBS INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Emergent BioSolutions Inc.
NEW YORK, NY / ACCESSWIRE / April 26, 2021 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors... 
From Bernstein Liebhard LLP
Via AccessWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
SHAREHOLDER ALERT: Robbins LLP Announces That Emergent BioSolutions Inc. (EBS) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
Exposures Product Safety
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Emergent BioSolutions Inc. (EBS) Investors
From Law Offices of Howard G. Smith
Via Business Wire
JNJ's COVID-19 Vaccine Halt Due To Blood-Clot Concerns To Be Scrutinized Today: WSJ
The U.S. is expected to announce its decision on Johnson & Johnson’s (NYSE: JNJ) single-shot COVID-19 vaccine on whether it should be back in circulation... 
Via Benzinga
Exposures COVID-19
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. (EBS)
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Renalytix AI (NASDAQ:RNLX) shares rose 21.41% to $30.62 during Thursday's regular session. Renalytix AI's stock is trading at a volume of 1.0 million... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.